Medicine & Life Sciences
Alzheimer Disease
100%
gantenerumab
38%
Amyloid
35%
Biomarkers
32%
Clinical Trials
28%
solanezumab
23%
Cognitive Dysfunction
18%
florbetapir
16%
Mutation
15%
Disease Progression
15%
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
15%
Cognition
14%
Sample Size
13%
Positron-Emission Tomography
12%
Multiple Sclerosis
10%
Mental Status and Dementia Tests
10%
Cerebrospinal Fluid
10%
Neuroimaging
10%
Apolipoprotein E4
7%
Brain
7%
Adaptive Clinical Trials
7%
Dementia
7%
Longitudinal Studies
7%
Psychological Power
6%
Amyloid Plaques
6%
Pharmaceutical Preparations
6%
Atrophy
6%
Pathology
6%
Asymptomatic Diseases
6%
Generic Drugs
5%
Relapsing-Remitting Multiple Sclerosis
5%
Intermediate Filaments
5%
Placebos
5%
Mathematics
Alzheimer's Disease
13%
Clinical Trials
8%
Biomarkers
6%
Sample Size Re-estimation
6%
Diagnostic Accuracy
6%
Randomized Trial
5%
Number of Clusters
5%
Statistical Power
5%
Breast Cancer
5%